Literature DB >> 11148550

Long-term management of patients with urea cycle disorders.

G T Berry1, R D Steiner.   

Abstract

The long-term treatment of patients with urea cycle disorders (UCDs) includes diet treatment and use of specific medications. Guidelines are provided for patients with a severe phenotype. However, treatment must be tailored for each individual, especially with regard to residual enzyme function and in vivo metabolic capacity. This will be reflected in tests used for monitoring therapy that should be performed on a periodic basis. The goal of therapy is to eliminate chronic complications, a laudable but rarely attainable goal. Sick-day rules are discussed. Chronic management also includes diverse services that are essential to the success of the metabolic program. These include neurologic and developmental evaluations, feeding team evaluation and therapy, physical and occupational therapies, speech therapy, school and educational services, social service intervention, psychologic services, and genetic counseling.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11148550     DOI: 10.1067/mpd.2001.111837

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  18 in total

Review 1.  Nutritional management of patients with urea cycle disorders.

Authors:  R H Singh
Journal:  J Inherit Metab Dis       Date:  2007-11-25       Impact factor: 4.982

2.  On the Creation, Utility and Sustaining of Rare Diseases Research Networks: Lessons learned from the Urea Cycle Disorders Consortium, the Japanese Urea Cycle Disorders Consortium and the European Registry and Network for Intoxication Type Metabolic Diseases.

Authors:  Marshall L Summar; Fumio Endo; Stefan Kölker
Journal:  Mol Genet Metab       Date:  2014 Sep-Oct       Impact factor: 4.797

Review 3.  Urea cycle disorders-update.

Authors:  Shirou Matsumoto; Johannes Häberle; Jun Kido; Hiroshi Mitsubuchi; Fumio Endo; Kimitoshi Nakamura
Journal:  J Hum Genet       Date:  2019-05-20       Impact factor: 3.172

4.  [Patients with ornithine transcarbamylase deficiency. Anaesthesiological and intensive care management].

Authors:  J Schmidt; M Schroth; A Irouschek; T Birkholz; M Kurzai; S Kröber; M Meisner; S Albrecht
Journal:  Anaesthesist       Date:  2005-12       Impact factor: 1.041

Review 5.  Inherited Metabolic Disorders: Aspects of Chronic Nutrition Management.

Authors:  Suzanne W Boyer; Lisa J Barclay; Lindsay C Burrage
Journal:  Nutr Clin Pract       Date:  2015-06-16       Impact factor: 3.080

Review 6.  An update on the use of benzoate, phenylacetate and phenylbutyrate ammonia scavengers for interrogating and modifying liver nitrogen metabolism and its implications in urea cycle disorders and liver disease.

Authors:  Javier De Las Heras; Luis Aldámiz-Echevarría; María-Luz Martínez-Chantar; Teresa C Delgado
Journal:  Expert Opin Drug Metab Toxicol       Date:  2016-11-28       Impact factor: 4.481

7.  Effects of arginine treatment on nutrition, growth and urea cycle function in seven Japanese boys with late-onset ornithine transcarbamylase deficiency.

Authors:  Hironori Nagasaka; Tohru Yorifuji; Kei Murayama; Mitsuru Kubota; Keiji Kurokawa; Tomoko Murakami; Masaki Kanazawa; Tomozumi Takatani; Atsushi Ogawa; Emi Ogawa; Shigenori Yamamoto; Masanori Adachi; Kunihiko Kobayashi; Masaki Takayanagi
Journal:  Eur J Pediatr       Date:  2006-05-16       Impact factor: 3.183

8.  Cross-sectional multicenter study of patients with urea cycle disorders in the United States.

Authors:  Mendel Tuchman; Brendan Lee; Uta Lichter-Konecki; Marshall L Summar; Marc Yudkoff; Stephen D Cederbaum; Douglas S Kerr; George A Diaz; Margaretta R Seashore; Hye-Seung Lee; Robert J McCarter; Jeffrey P Krischer; Mark L Batshaw
Journal:  Mol Genet Metab       Date:  2008-06-17       Impact factor: 4.797

Review 9.  Ammonia toxicity to the brain.

Authors:  Olivier Braissant; Valérie A McLin; Cristina Cudalbu
Journal:  J Inherit Metab Dis       Date:  2012-10-30       Impact factor: 4.982

10.  Arginine and asymmetric dimethylarginine in pregnant women with major depression.

Authors:  Alexander Raw; Marcia Gallaher; Robert W Powers
Journal:  Psychosom Med       Date:  2014 Jul-Aug       Impact factor: 4.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.